Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
123.00
-2.89 (-2.30%)
Streaming Delayed Price
Updated: 1:15 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
87
88
Next >
Could This Be Merck's Next Blockbuster Drug?
March 18, 2023
Merck recently shared encouraging clinical trial results for its cholesterol-lowering drug candidate.
Via
The Motley Fool
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
March 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
This High-Growth Company Is Expanding. Time to Buy the Stock?
March 16, 2023
Moderna shares have lost about 15% so far this year.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
March 16, 2023
Via
Benzinga
A Look Into Merck & Co's Debt
March 10, 2023
Via
Benzinga
Expert Ratings for Merck & Co
March 10, 2023
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
March 09, 2023
Via
Benzinga
Why OPKO Health Shares Jumped on Wednesday
March 08, 2023
A major pharma name is showing interest in one of the company's vaccine prospects.
Via
The Motley Fool
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
March 15, 2023
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
Via
MarketBeat
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
March 14, 2023
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
March 13, 2023
Via
Benzinga
Merck Highlights Promising Data From Two Candidates In Heart Diseases
March 06, 2023
Via
Benzinga
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
March 13, 2023
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis.
Via
Benzinga
Stock Market Tumbles Amid SVB Financial Collapse, 'Faster' Powell: Weekly Review
March 10, 2023
The major indexes suffered serious losses this past week.
Via
Investor's Business Daily
Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma
March 10, 2023
Merck & Co Inc (NYSE: MRK) announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial of Keytruda plus chemotherapy combo met its primary endpoint in unresectable advanced or metastatic malignant...
Via
Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
March 10, 2023
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to...
Via
Benzinga
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
March 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF
March 08, 2023
Dividend funds like the SCHD ETF are gaining traction ahead of its March 27 dividend payment. What are the top 10 holdings in the ETF?
Via
InvestorPlace
OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck
March 08, 2023
Via
Benzinga
2 Top Healthcare Stocks to Buy Right Now
March 08, 2023
Most people eventually need the healthcare goods/services that these companies provide.
Via
The Motley Fool
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Merck to Present at the Barclays 2023 Global Healthcare Conference
March 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
Beat the Dow Jones With This Unstoppable Dividend Stock
March 08, 2023
Merck had a strong year and has the portfolio and pipeline to increase its dividend.
Via
The Motley Fool
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
March 07, 2023
Via
Benzinga
Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
March 07, 2023
Via
Benzinga
Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart Drugs
March 07, 2023
The heart segment is becoming more important as Keytruda near patent expiration.
Via
Investor's Business Daily
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
March 07, 2023
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at...
Via
Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
March 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
March 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
87
88
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.